Successful completion of global phase I/II clinical trial for Galnobax

Galnobax is a topical gel for treatment of Diabetic Foot Ulcer (DFU). It has the potential to be the First Small Molecule drug for Diabetic foot ulcer. The last new drug approved for DFU by USFDA was in 1997


(Photo Courtesy:

Pune-based NovaLead Pharma, a drug discovery and development company, announced a potential breakthrough in the treatment of diabetic foot ulcers (DFU), which is a frequent complication of uncontrolled diabetes over a period of time.

The recently concluded global Phase I/II clinical trial of its repositioned investigational drug, Galnobax successfully met both primary and secondary end points for efficacy and safety.

The scientific challenge in this discovery can be understood by the fact that the last and the only USFDA approved drug for DFU came in 1997.

The gel can be self-administered at home without significant side-effects thus providing additional benefits to patients in terms of convenience and saving hospital costs

In this trial, Galnobax demonstrated significant benefit over placebo in terms of ability to close hard to heal DFUs in much shorter time, making it potentially the first small molecule drug for DFU.


Previous 1 3 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email